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ABSTRACT
Objective To investigate the association between
treatment induced change in high density lipoprotein
cholesterolandtotaldeath,coronaryheartdiseasedeath,
andcoronaryheartdiseaseevents(coronaryheartdisease
death and non-fatal myocardial infarction) adjusted for
changes in low density lipoprotein cholesterol and drug
classinrandomisedtrialsoflipidmodifyinginterventions.
DesignSystematicreviewandmeta-regressionanalysisof
randomised controlled trials.
Data sources Medline, Embase, Central, CINAHL, and
AMED to October 2006 supplemented by contact with
experts in the field.
Study selectionIn teams of two, reviewersindependently
determinedeligibilityofrandomisedtrialsthattestedlipid
modifying interventions to reduce cardiovascular risk,
reported high density lipoprotein cholesterol and
mortality or myocardial infarctions separately for
treatment groups, and treated and followed participants
for at least six months.
Data extraction and synthesis Using standardised, pre-
pilotedforms,reviewersindependentlyextractedrelevant
information from each article. The change in lipid
concentrations for each trial and the weighted risk ratios
for clinical outcomes were calculated.
Results The meta-regression analysis included 108
randomisedtrialsinvolving299310participantsatriskof
cardiovascular events. All analyses that adjusted for
changesinlowdensitylipoproteincholesterolshowedno
association between treatment induced change in high
densitylipoproteincholesterolandriskratiosforcoronary
heart disease deaths, coronary heart disease events, or
total deaths. With all trials included, change in high
density lipoprotein cholesterol explained almost no
variability(<1%)inanyoftheoutcomes.Thechangeinthe
quotient of low density lipoprotein cholesterol and high
densitylipoproteincholesteroldidnotexplainmoreofthe
variability in any of the outcomes than did the change in
low density lipoprotein cholesterol alone. For a 10 mg/dl
(0.26 mmol/l) reduction in low density lipoprotein
cholesterol, the relative risk reduction was 7.2% (95%
confidence interval 3.1% to 11%; P=0.001) for coronary
heart disease deaths, 7.1% (4.5% to 9.8%; P<0.001) for
coronary heart disease events, and 4.4% (1.6% to 7.2%;
P=0.002) for total deaths, when adjusted for change in
high density lipoprotein cholesterol and drug class.
ConclusionsAvailabledatasuggestthatsimplyincreasing
the amount of circulating high density lipoprotein
cholesterol does not reduce the risk of coronary heart
disease events, coronary heart disease deaths, or total
deaths. The results support reduction in low density
lipoprotein cholesterol as the primary goal for lipid
modifying interventions.
INTRODUCTION
Large cohort studies have identified high density
lipoprotein cholesterol as a strong, independent,
inverse predictor of risk of coronary heart disease.
1-4
Although the inverse relation seems not to apply to
particular subgroups of patients with genetic varia-
tions, such as ABCA1 or cholesteryl ester transfer
protein mutations leading to abnormal low or high
levels of high density lipoprotein cholesterol,
56 the
National Cholesterol Education Program has recog-
nised high density lipoprotein cholesterol as an
independent cardiovascular risk factor and recom-
mended screening measurements of high density
lipoprotein cholesterol for all adults.
7-9
The association between high density lipoprotein
cholesterol concentrations and coronary heart disease
in observational studies does not, however, establish
theextenttowhichchangesinhighdensitylipoprotein
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events. Many large randomised trials and meta-
analyses led to the identification of low density
lipoprotein cholesterol as the principal target for lipid
modifying interventions.
89Evidence that raising high
density lipoprotein cholesterol will reduce cardio-
vascular adverse outcomes remains controversial.
Clinical trials of the high density lipoprotein raising
agent niacin have shown a reduction in coronary
events,butthesetrialseitherdidnotmeasurechangein
highdensitylipoproteincholesterolorfailedtoinclude
analyses adjusted for changes in low density lipopro-
tein cholesterol.
10-14 Sub-studies of two trials using the
fibrate gemfibrozil suggested that an increase in high
density lipoprotein cholesterol reduces the risk of
coronary heart disease.
1516 In the Veterans Affairs
High-Density Lipoprotein Cholesterol Intervention
Trial (VA-HIT), a multivariable analysis adjusting for
several coronary heart disease risk factors and on-
treatment low density lipoprotein cholesterol and
triglycerides suggested an independent association of
increased high density lipoprotein cholesterol with
reductionincoronaryheartdiseasedeathandnon-fatal
myocardial infarction. However, the VA-HIT investi-
gators also found that on-treatment lipid concentra-
tions as variables in a multivariable model explained
only a small amount of the beneficial effect of
gemfibrozil.
15Newapproachestoincreasehighdensity
lipoproteincholesterolbythecholesterylestertransfer
protein inhibitor torcetrapib or by infusion of recon-
stituted high density lipoprotein failed to show
beneficial effects.
17-20 As part of a systematic review of
lipidtrialspublishedupto2001,ananalysisfocusingon
19 statin trials failed to establish a statistically
significantassociationbetweenchangesinhighdensity
lipoprotein cholesterol and relative risk reductions for
patient important outcomes.
21
We used meta-regression techniques in an updated,
morecomprehensivesystematicreviewofrandomised
trials to explore an independent link between changes
in high density lipoprotein cholesterol, not limited to
statins but covering all lipid modifying treatment, and
coronary heart disease related morbidity and mortal-
ity.
METHODS
Data sources and searches
We included studies if they compared any lipid
modifying agent or diet with placebo or usual care or
compared a more intensive with a less intensive lipid
modifying treatment; targeted reduction in cardio-
vascular risk; had a randomised control design;
reported mortality or myocardial infarctions sepa-
ratelyfortreatmentgroups;andfollowedpatientsforat
least six months. We excluded studies that failed to
report either change from baseline or follow-up
concentrations of high density lipoprotein cholesterol
and low densitylipoprotein cholesterol and studies for
which critics have raised serious questions about the
integrity of the data.
2223
We built our search for relevant studies on the
sensitive search strategies used in previous systematic
reviews supplemented with relevant keywords and
medical subject headings.
2124-28 To update this evi-
dence,MBandNB(anexperiencedlibrarian)searched
Medline, Embase, and Central (all from January 2003
to October 2006) in addition to CINAHL and AMED
(both from their inception to October 2006). We used
Cochrane sensitive search strategies for identifying
randomised trials and made no restriction as to
language. The detailed search strategy is available
from the authors. We reviewed reference lists of
eligible articles, recently published editorials, and
reviews on the topic and consulted with experts.
Study selection and quality assessment
Investigators trained in research methods worked in
pairs and independently reviewed potentially eligible
titles and abstracts. If either reviewer believed that the
study might be eligible, we obtained the full report.
Two investigators then independently assessed the
eligibility of each article by using a pilot tested,
standardised form with written instructions. We did
calibration exercises to enhance consistency among
review teams before using the forms for eligibility
assessmentanddataextraction.Anydisagreementwas
resolved by consensus or third party arbitration (MB).
We used Cohen’s κ to measure agreement beyond
chance between reviewers.
29 Two reviewers indepen-
dently assessed the methodological quality of each
eligible study by using the following criteria: conceal-
ment of allocation; blinding of patients, caregivers, or
clinical outcome assessors; adherence to the intention
to treat principle; stopping early for benefit; and the
proportion of patients lost to follow-up.
30
Potentially relevant articles identified
and screened for retrieval (n=10 532)
Articles retrieved in full text for more detailed evaluation (n=572)
RCTs included in meta-analysis (n=108)
RCTs with usable information, by outcome (n=108)
Articles excluded on basis of title and
abstract by using inclusion criteria (n=9960)
Articles excluded (n=414): 
  Not aiming at cardiovascular risk (n=10)
  No parallel-group RCT (n=21)
  Not reporting deaths or MIs per group (n=173)
  Follow-up <6 months (n=134)
  Duplicates, protocols, substudies of trials (n=76)
RCTs excluded (n=50):
  No follow-up values reported for LDL and HDL cholesterol
Potentially appropriate RCTs to be
included in meta-analysis (n=158)
Flowchart of trials. HDL=high density lipoprotein; LDL=low
density lipoprotein; MI=myocardial infarction;
RCT=randomised controlled trial
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Twoinvestigatorsindependentlyextractedallrelevant
informationonbaselinecharacteristicsoftrials,patient
populations, interventions, and outcomes from each
eligible article by using standardised, pre-piloted data
extraction forms. We recorded all available baseline
and follow-up concentrations of total cholesterol, low
density lipoprotein cholesterol, high density lipopro-
tein cholesterol, and triglycerides. In five trials that
failed to report exact lipid concentrations, we
abstracted data from graphs. Clinical end points were
total deaths, coronary heart disease deaths, and
coronary heart disease events (combined outcome of
non-fatal myocardial infarction and coronary heart
disease death). For coronary heart disease death, we
extracted data by using the following hierarchy:
coronary heart disease death, fatal myocardial infarc-
tionandsuddendeath,fatalmyocardialinfarction,fatal
cardiac events, fatal cardiovascular events.
Data synthesis and analysis
We report means and standard deviations of lipid
concentrations as milligrams per decilitre; we used the
method of Hozo to convert data reported as median
and range,
31 and we followed the recommendations of
the Cochrane methods group for data reported as
median and 25th and 75th centiles.
32 We calculated
change in lipid concentrations for each trial as the
difference between the mean change in the lipid
concentration from baseline to the average follow-up
concentrations in the intervention and control groups.
Wepooledtreatmenteffectsacrossstudiesby calculat-
ing inverse variance weighted average risk ratios and
associated 95% confidence intervals for specified
outcomes by using a random effects model.
We used inverse variance weighted meta-regression
analysis to investigate the association between differ-
ences in the change in high density lipoprotein
cholesterol and low density lipoprotein cholesterol
concentrations between treatment and control groups
and the risk ratios of clinical outcomes of interest.
3334
To take into account non-lipid effects of specific drugs
(such as potential pro-thrombotic effects of hormone
therapy), we included a categorical variable of drug
class in the meta-regression model and did a meta-
regressionanalysisstratifiedbydrugclass.WeusedR
2
to measure the proportion of the variability in the log
risk ratio of an outcome explained by the statistical
model.Weanalysedresidualstocheckmodelassump-
tions. To determine whether the potential relation
between treatment induced changes in high density
lipoprotein cholesterol and risk ratios for coronary
heart disease events varied across drug classes, we
tested for interactions between change in high density
lipoprotein cholesterol and different classes of inter-
ventionsbymeansofanFtest.Wefoundlittleevidence
for interaction (P=0.73). That is, our analysis provided
no support for the hypothesis that increase in high
density lipoprotein cholesterol had a greater effect on
patientimportantoutcomeswithsomedrugsthanwith
others. Therefore, we omitted interaction terms to
simplify the final model. Analyses with percentage
change in lipid subfractions yielded similar results to
analyses with absolute change (mg/dl) and are there-
fore not reported.
Inpre-specifiedsensitivityanalyses,wefocusedona
more homogeneous sample of trials that used inter-
ventions known to raise high density lipoprotein
cholesterolconcentrations(ratherthanreducingtrigly-
cerides) and therefore excluded trials using n-3 fatty
acids,lowfatdiets,orprobucol,aswellastrialsfocusing
onpatientswithrenalfailure.Inaddition,weexcluded
trials with agents that are associated with harmful
effectssuchastorcetrapiborhormones.Wedidfurther
pre-specified sensitivity analyses excluding trials with
one year or less of follow-up and excluding trials with
Table 1 |Effects of different lipid modifying interventions on lipid subfractions. Values are weighted mean (SD) unless stated otherwise
Trials
No. of
trials
Noofrandomised
participants
Median(interquartile
range) follow-up
(months)
Total cholesterol
(mg/dl)
LDL cholesterol
(mg/dl)
HDL cholesterol
(mg/dl)
Triglycerides
(mg/dl)
Baseline Change Baseline Change Baseline Change Baseline Change
All trials 111* 299 310 34 (24-54) 222 (23) −27 (22) 140 (23) −23 (19) 47.3 (7.4) 1.7 (3.1) 155 (19) −15 (18)
Statins 62 157 151 32 (24-51) 221 (25) −43 (15) 142 (24) −38 (13) 44.7 (5.5) 1.6 (1.5) 156 (18) −21 (9)
Fibrates 9 22 370 60 (55-60) 213 (32) −15 (7) 138 (29) −8.9 (6.7) 41.1 (4.9) 2.6 (2.3) 162 (16) −44 (14)
Resins 3 4 005 60 (39-89) 280 (4) −23 (7) 206 (6) −25 (8) 44.2 (1.2) 2.7 (0.5) 155 (6) 6.1 (1)
Combinations
with niacin
6 779 27 (24-30) 231 (65) −41 (28) 156 (57) −42 (28) 39.9 (5.4) 12 (3.0) 166 (26) −48 (30)
n-3fattyacids 9 13 768 24 (12-27) 216 (14) 1.1 (2.2) 142 (13) 7.6 (1.9) 41.8 (1.9) −0.1 (0.3) 166 (11) −12 (15)
Diet/surgery 5 62 645 78 (39-97) 228 (7) −4.0 (6) 139 (10) −6.4 (8.4) 55.5 (7.2) −0.1 (0.4) 152 (23) 0.8 (5)
ACAT
inhibitors
2 717 12 (6-18) 179 −23 106 −2.1 42.5 −0.3 156 −10
Probucol 2 481 16 (7-24) 242 −31 160 −19 48.2 −12.3 171 1.1
Glitazones 2 9 589 42 (36-48) 204 NA 116 3.6 44.5 3.1 162 −15
Hormones 9 25 710 38 (24-49) 226 (6) −2.4 (1.4) 132 (9) −13 (5) 53.1 (2.3) 4.3 (3.1) 148 (17) 26 (11)
Torcetrapib
(+ statin)
2 2 095 24 (24-24) 182 5.1 107 −21 48.5 27.7 112 −6.2
ACAT=acyl-CoA:cholesterol acyltransferase; HDL=high density lipoprotein; LDL=low density lipoprotein; NA=not available.
*Includes three studies with three trial arms; excludes one study that did not report baseline values (only change during follow-up).
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more than a year to fully translate into clinical
effects.
3536 In response to reviewers’ comments, we
added a sensitivity analysis focusing on trials with
interventions specifically chosen to raise high density
lipoprotein cholesterol (fibrates and niacin combina-
tions) and another focusing on trials that reported
intention to treat results. Finally, we investigated the
association of treatment induced change in triglycer-
idesconcentrationswithclinicaloutcomesbyusingthe
same approach as for high density lipoprotein choles-
terol.WeusedSASversion9.1foranalyses.Wesetthe
threshold for statistical significance at P<0.05.
RESULTS
Of158eligiblerandomisedcontrolledtrials,50didnot
reportchangeorfollow-upvaluesforbothhighdensity
lipoprotein cholesterol and low density lipoprotein
cholesterol and were therefore excluded, leaving 108
trials for analysis (figure). Three of these 108 trials had
multiple treatment arms, so we used the control group
for comparison against all treatment arms. In total,
146890 participants were included in the intervention
groups and 152420 in the control groups. The web
appendix summarises the methodological quality
assessment of included trials and characteristics of
patient populations. On the basis of pharmacological
characteristics, we classified trials according to the
following classes of intervention
37: statins (54 trials
comparing statins with placebo or usual care
w1-w54 and
eight trials comparing more intensive with less
intensive statin treatment
w55-w62); fibrates (nine
trials
w63-w71); resins (three trials
w72-w74); niacin combina-
tionswithastatin,fibrate,orresin(sixtrials
A1;A75-A79);n-
3 fatty acids (nine trials
w80-w88); acyl-CoA:cholesterol
acyltransferase inhibitors (two trials
w92 w93); probucol
(two trials
w21 w94); glitazones (two trials
w95 w96); hor-
mones (nine trials
w97-w105); torcetrapib (two trials
w106
w107); low fat diets and surgery (five trials
w74 w89-w91 w108).
Agreementbetween reviewers for studyeligibility was
very high (κ range 0.84-0.94).
Lipid modifying effects
Table 1 summarises the baseline concentrations and
changes in lipid subfractions for the different classes of
intervention.Theaverageweightedmeanbaselinelow
density lipoprotein cholesterol concentration of all
included participants was 140 (SD 23; range 84-279)
mg/dl (3.62 mmol/l), and the high density lipoprotein
cholesterol concentration was 47 (7.4; 32-62) mg/dl
(1.22 mmol/l). The weighted mean change in low
density lipoprotein cholesterol was −23 (SD 19) mg/dl
(−0.59mmol/l),andtheweightedmeanchangeinhigh
density lipoprotein cholesterol was 1.7 (3.1) mg/dl
(0.04 mmol/l). Almost all classes of intervention
reduced low density lipoprotein cholesterol except
for n-3 fatty acids and glitazones. High density
lipoprotein cholesterol was raised by most classes of
intervention except for n-3 fatty acids, low-fat diets,
acyl-CoA:cholesterol acyltransferase inhibitors, and
probucol. In addition, high dose statin treatment
(defined as 80 mg daily simvastatin or atorvastatin)
slightly reduced high density lipoprotein cholesterol
compared with less intensive statin treatment
(weighted mean change −0.23 (SD 0.83) mg/dl),
w56-
w59 w61 w62 whereas statins overall raised it moderately
(weighted mean change 1.6 (1.5) mg/dl).
Meta-regression analysis for clinical outcomes
Change in low density lipoprotein cholesterol was
associated with and explained a statistically significant
degree of variability in the log risk ratio for coronary
heartdiseaseevents,coronaryheartdiseasedeath,and
total death in univariable and multivariable meta-
regression analysis adjusted for change in high density
lipoprotein cholesterol and different drug classes
(table 2). For example, the risk ratio for coronary
heart disease events (death or non-fatal myocardial
infarction) was reduced, on average, by 7.1% (95%
confidence interval 4.5% to 9.8%; P <0.001) per
Table 2 |Meta-regression models investigating association of change in HDL cholesterol, LDL
cholesterol, or both with log risk ratios of clinical outcomes
Regression model and
predictor
Change in risk per 10 mg/dl increase in lipid
subfraction—% (95% CI) P value R2*
CHD events (CHD death and non-fatal MI) (n= =95)† †
Univariable:
Change in LDL 4.9 (3.4 to 6.5) <0.001 0.32
Change in HDL −8.2 (−24.7 to 8.1) 0.32 0.01
Bivariable:
Change in LDL 5.1 (3.6 to 6.7) <0.001
0.33
Change in HDL 6.4 (−7.8 to 20.4) 0.37
Multivariable‡:
Change in LDL 7.1 (4.5 to 9.8) <0.001
0.46
Change in HDL 16.0 (−4.2 to 36.9) 0.12
Total death (n= =107)† †
Univariable:
Change in LDL 2.8 (1.4 to 4.3) <0.001 0.12
Change in HDL 5.5 (−8.5 to 19.2) 0.44 0.01
Bivariable:
Change in LDL 3.1 (1.7 to 4.6) <0.001
0.15
Change in HDL 12.1 (−1.1 to 25.2) 0.07
Multivariable‡:
Change in LDL 4.4 (1.6 to 7.2) 0.002
0.28
Change in HDL 11.0 (−6.5 to 28.1) 0.21
CHD death (n= =94)† †
Univariable:
Change in LDL 4.5 (2.4 to 6.6) <0.001 0.16
Change in HDL −0.2 (−24.0 to 23.1) 0.99 <0.01
Bivariable:
Change in LDL 4.8 (2.6 to 7.0) <0.001
0.17
Change in HDL 11.3 (−10.8 to 32.9) 0.31
Multivariable‡:
Change in LDL 7.2 (3.1 to 11.3) 0.001
0.33
Change in HDL 12.2 (−18.0 to 41.5) 0.42
CHD=coronary heart disease; HDL=high density lipoprotein; LDL=low density lipoprotein; MI=myocardial
infarction.
*Proportion of total variability in log risk ratio of outcome explained by model.
†Absence of outcome events in intervention and control groups or absence of reporting this outcome event led
to reduced sample of trials.
‡Models include adjustment for drug class in addition to variables of lipid subfractions.
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lipoprotein cholesterol in a multivariable model.
Change in low density lipoprotein cholesterol
explained 32% of the variability in the log risk ratio
for coronary heart disease events (see R
2 for univari-
able model with low density lipoprotein cholesterol in
table 2).
Wefoundnosignificantassociationofchangeinhigh
densitylipoproteincholesterolwiththelogriskratioin
any model after adjustment for changes in low density
lipoprotein cholesterol (see table 2 and results of
analyses stratified by drug class in web table A). For
example, the risk ratio for coronary heart disease
events was increased, on average, by 16% (−4.2% to
36.9%; P=0.12) per 10 mg/dl increase in high density
lipoprotein cholesterol according to our multivariable
model in table 2. Change in high density lipoprotein
cholesterol hardly explained any variability in any of
theoutcomes(seeR
2resultsintable 2andwebtableA).
The change in the quotient of low density lipoprotein
cholesterol and high density lipoprotein cholesterol
explained 32%, 12%, and 15% of the variability in log
riskratiosforcoronaryheartdiseaseevents,totaldeath,
and coronary heart disease death, which is no more
than the change in low density lipoprotein cholesterol
alone explained for these outcomes (see R
2 results for
univariable models with low density lipoprotein
cholesterol in table 2).
Sensitivity analyses focusing on a more homoge-
neous sample of trials (interventions known to raise
high density lipoprotein cholesterol and excluding
trials using agents associated with harmful effects)
revealed a significant association of change in high
densitylipoproteincholesterolandthelogriskratiofor
coronary heart disease events in univariable analysis,
with a 29% (51.7% to 6.6%; P=0.01) risk reduction for
each 10 mg/dl increase in high density lipoprotein
cholesterol(table 3).Thisassociationwas,however,no
longerdetectableinmodelsadjustedforchangesinlow
density lipoprotein cholesterol (bivariable or multi-
variable), indicating that the apparent reduction in
outcomeswasduetotheassociationofchangesinhigh
density lipoprotein cholesterol with changes in low
density lipoprotein cholesterol. Change in low density
lipoprotein cholesterol remained significantly asso-
ciated with the log risk ratio for coronary heart disease
events, explaining greater variability in trials that had
longer follow-up (R
2 of 0.41, 0.46, and 0.51 for trials
witha follow-upofsixmonthsormore,morethanone
year, and more than two years). Two additional
sensitivity analyses focusing on trials with inter-
ventions specifically chosen to raise high density
lipoprotein cholesterol and on trials reporting inten-
tion to treat results did not show any significant
association of change in high density lipoprotein
cholesterol with risk of coronary heart disease events.
Similarly, we found no association between change
in triglycerides and risk of coronary heart disease
eventswheneverthemodelincludedanadjustmentfor
the change in low density lipoprotein cholesterol (data
available from the authors). Change in low density
Table 3 |Sensitivity analyses for outcome of coronary heart disease death and non-fatal
myocardial infarction with different samples of trials*
Regression model and
predictor
Change in risk per 10 mg/dl increase in lipid
subfraction—% (95% CI) P value R2†
TrialsusinginterventionsknowntoraiseHDLcholesterol,excludingtrialsusingagentsassociatedwithharmful
effects‡ ‡
Follow-up ≥ ≥6 months (n= =70)
Univariable:
Change in LDL 5.5 (3.9 to 7.0) <0.001 0.41
Change in HDL −28.9 (−51.7 to −6.6) 0.01 0.09
Bivariable:
Change in LDL 5.4 (3.6 to 7.2) <0.001
0.41
Change in HDL −2.2 (−22.1 to 17.4) 0.83
Multivariable§:
Change in LDL 6.9 (4.2 to 9.6) <0.001
0.51
Change in HDL 15.2 (−8.2 to 38.1) 0.20
Follow-up >1 year (n= =59)
Univariable:
Change in LDL 5.5 (4.0 to 7.1) <0.001 0.46
Change in HDL −29.0 (−52.7 to −5.9) 0.02 0.10
Bivariable:
Change in LDL 5.5 (3.7 to 7.2) <0.001
0.46
Change in HDL −2.0 (−22.0 to 17.6) 0.84
Multivariable§:
Change in LDL 7.1 (4.5 to 9.8) <0.001
0.58
Change in HDL 16.2 (−7.0 to 38.8) 0.17
Follow-up >2 years (n= =49)
Univariable:
Change in LDL 5.6 (4.0 to 7.2) <0.001 0.51
Change in HDL −27.5 (−53.6 to −2.0) 0.04 0.09
Bivariable:
Change in LDL 5.7 (3.9 to 7.5) <0.001
0.52
Change in HDL 3.1 (−17.9 to 23.7) 0.77
Multivariable§:
Change in LDL 7.5 (4.8 to 10.1) <0.001
0.63
Change in HDL 22.4 (−1.4 to 45.7) 0.06
TrialsusinginterventionsspecificallychosentoraiseHDLcholesterol(niacincombinationsandfibrates)(n= =13)
Univariable:
Change in LDL 5.7 (−102 to 20.8) 0.44 0.07
Change in HDL −10.1 (−61.8 to 39.2) 0.55 0.04
Bivariable:
Change in LDL 5.0 (−16.1 to 24.7) 0.62
0.06
Change in HDL −5.0 (−74.7 to 60.1) 0.89
Multivariable§:
Change in LDL −2.3 (−23.7 to 18.6) 0.81
0.30
Change in HDL −6.3 (−70.6 to 54.2) 0.82
Trials with intention to treat data (n= =78)
Univariable:
Change in LDL 4.9 (3.4 to 6.5) <0.001 0.35
Change in HDL −11.7 (−30.4 to 6.7) 0.21 0.02
Bivariable:
Change in LDL 5.0 (3.4 to 6.6) <0.001
0.35
Change in HDL 2.6 (−13.2 to 18.1) 0.74
Multivariable§:
Change in LDL 7.1 (4.1 to 10.0) <0.001
0.47
Change in HDL 11.1 (−13.6 to 35.2) 0.37
HDL=high density lipoprotein; LDL=low density lipoprotein.
*I
2 associated with risk ratios for coronary heart disease events was 41.1% (95% uncertainty interval 24.5% to
54.0%) in all trials (n=95), 28.3% (3.4% to 46.8%) in trials using interventions known to raise HDL cholesterol
and excluding trials using agents associated with harmful effects (n=70), and 13.3% (0% to 52.5%) in trials
using interventions specifically chosen to raise HDL cholesterol (n=13).
†Proportion of total variability in log risk ratio of outcome explained by model.
‡Excluding trials using n-3 fatty acids, low fat diets, probucol, torcetrapib, and hormones and trials focusing on
patients with renal failure.
§Models include adjustment for drug class in addition to variables of lipid subfractions.
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cant predictor in a multivariable model adjusting for
change in high density lipoprotein cholesterol, change
in triglycerides, and class of intervention, with a 7.4%
(4.4% to 10.4%; P <0.001) relative risk reduction for
coronary heart disease events.
Model residuals were normally distributed with
constant variance (homoscedasticity). Including quad-
ratic or exponential terms did not improve the fit of
models. We found no evidence of collinearity.
DISCUSSION
Thissystematicreviewandmeta-regressionanalysisof
108randomisedcontrolledtrialsusinglipidmodifying
interventions did not show an association between
treatmentmediatedchangeinhighdensitylipoprotein
cholesterol and risk ratios for coronary heart disease
events, coronary heart disease deaths, or total deaths
whenever change in low density lipoprotein choles-
terol was taken into account. We found a statistically
significant, substantial association between change in
low density lipoprotein cholesterol and risk ratios for
coronary heart disease events, coronary heart disease
deaths, or total deaths, adjusted for other lipid
subfractions and drug class. Our results indicate a 7%
relativeriskreductionincoronaryheartdiseaseevents
for every 10 mg/dl (0.26 mmol/l) reduction in low
densitylipoproteincholesterol,whichisequivalenttoa
10%relativereductionincoronaryheartdiseaseevents
for every 10% decrease in low density lipoprotein
cholesterol; this is consistent with the magnitude of
reduction reported in current National Cholesterol
Education Program guidelines.
8
Strengths and limitations
Strengths of this study include a comprehensive scope
that included a wide range of patients at risk of
cardiovascular events and a wide variety of lipid
modifying interventions, maximising the power of
our analysis. Our extensive literature search supple-
mentedbycontactingexpertsinthefieldtoretrieveall
relevant eligible trials minimised the potential for
publication bias, but we cannot exclude it completely.
We could not include 50 otherwise eligible trials that
failed to measure or did not report follow-up values or
change in low density lipoprotein cholesterol or high
density lipoprotein cholesterol (for details see web
appendix). Unidentified trials or trials that failed to
report data on high density lipoprotein cholesterol or
low density lipoprotein cholesterol reduced the power
of our analysis but were unlikely to bias its results.
A meta-regression such as ours relies on variability
across studies in both the differences between high
density lipoprotein cholesterol in treatment and con-
trolgroupsandvariabilityinmagnitudeofeffect.Thus,
the analysis is powerful to the extent that it includes
studiesinwhichdifferencesinhighdensitylipoprotein
cholesterol are modest (such as with statins) or non-
existent and studies in which differences are large
(niacin). Our analysis would have been stronger if we
hadhadaccesstodatafromadditionalstudiesinwhich
differences in changes in high density lipoprotein
cholesterol between treatment and control were large.
Nevertheless, variability was sufficient that if a strong
effectofhighdensitylipoproteincholesterolexistedwe
would probably have detected it.
To limit the risk of data driven spurious associations
and overfitting, we pre-specified a limited number of
predictors for our statistical models.
38 We verified the
modelassumptionsoflinearity,normalityofresiduals,
homoscedasticity, and absence of collinearity. In
addition, our results proved robust in several pre-
specified sensitivity analyses and were consistent with
other investigations that have examined similar data.
8
Oursystematicreviewisfarmorecomprehensivethan
previous studies on this subject.
21
Nevertheless, the relation described by a meta-
regression is observational—that is, although the
original studies may be randomised trials, a meta-
regression across trials does not have the benefit of
randomisation to support a causal interpretation and
thus risks bias by confounding. Moreover, regression
analysis typically ignores the effect of measurement
errorsintheindependentvariables.Althoughthismay
beproblematictotheextentthatolderstudiesusedless
precise methods to determine lipid subfractions, our
meta-regression involves mean values of the indepen-
dent variables. The standard errors of these means are
substantially smaller than the standard deviations of
individual participants’ values, which should mitigate
the problem.
Our classification of lipid modifying interventions
may be argued to combine antilipidaemic agents and
diets that have important pharmacological differences
or mechanisms of action
37—for example, in trials
classified under niacin treatment, niacin could be
combined with a statin, a fibrate, or a resin. Different
interventions that alter high density lipoprotein cho-
lesterol may have different impacts on cardiovascular
risk. Interventions may lead to different types of high
density lipoprotein cholesterol with differences in
function (see below); they may raise high density
lipoprotein cholesterol by reduced catabolism (which
may be detrimental) or increased production (more
likely to be beneficial). Our adjustment of the analysis
by type of intervention (drug class) deals with this
problem to a considerable extent but may not fully
solve it.
Finally, meta-regression relies on aggregated data
from studies rather than data from individual patients
—thatis,therelationwithpatientaveragesacrosstrials
may not be the same as the relation for patients within
trials. This is known as the ecological fallacy.
34 There-
fore, ideally our results would be confirmed by an
analysis of data from individual patients, with a large
pooled dataset of trials testing lipid modifying inter-
ventions, such as data from the Cholesterol Treatment
Trialists’ Collaborators.
39
New views on high density lipoprotein cholesterol
Our findings contributeto accumulatingevidence that
simply increasing the amount of circulating high
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confer cardiovascular benefits.
17-2040 In the case of
torcetrapib, one of the most potent high density
lipoproteinraisingagentstodate,thefailuretoimprove
intracoronary atheroma burden in ultrasound studies
and the excess mortality seen in the Investigation of
Lipid Level Management to Understand its Impact in
Atherosclerotic Events (ILLUMINATE) trial may be
explained by a molecule specific increase in blood
pressure(perhapsowingtoincreasedconcentrationsof
aldosterone)orunforeseeninteractionsbetweentorce-
trapib and atorvastatin.
1718204142 Recent data suggest
the former possibility
43; if so, other cholesteryl ester
transfer protein inhibitors may still hold promise.
An alternative hypothesis would suggest that inhibi-
tion of the cholesteryl ester transfer protein leads to
production of dysfunctional high density lipoprotein
cholesterol with pro-inflammatory and atherogenic
properties.
4445 High density lipoprotein cholesterol
particles vary substantially in size, density, composi-
tion, and functional properties. The varying function-
ality of different high density lipoprotein cholesterol
subfractions most likely affects their relation to
atherosclerosis.
46-48 Lipid modifying agents and diets
mayaffectthe functionalityofhighdensitylipoprotein
cholesterol.Forexample,recentdatasuggestthatalow
fat, high fibre diet, in combination with exercise,
converts high density lipoprotein cholesterol from a
pro-inflammatory to an anti-inflammatory state.
49
Available measures of the function of high density
lipoprotein cholesterol include indices of inflamma-
tion, oxidation, monocyte chemotaxis, nitric oxide
production, endothelial function, and thrombosis, as
well as tests assessing the reverse cholesterol transport
effects of treatments.
50 However, further development
isnecessarytosatisfytheurgentneedforareliableand
easily applicable assay of high density lipoprotein
cholesterol function.
Implications for clinical practice and future research
The lack of association between treatment induced
change in high density lipoprotein cholesterol and the
risk of coronary heart disease events, coronary heart
diseasedeaths,ortotaldeathsraisesquestionsaboutthe
rationale for development of therapeutic agents that
increase high density lipoprotein cholesterol. Raising
high density lipoprotein cholesterol without consider-
ingeffectsonhighdensitylipoproteinfunctionseemto
havelittlepromiseforthepreventionofcardiovascular
events. Future research should prospectively consider
theresultsofassaystomeasurehighdensitylipoprotein
function and then provide definitive evidence of
pharmacological effects on patient important out-
comes in long term randomised trials.
50
Results from this study corroborate recommenda-
tionsfromcurrentclinicalguidelines(AdultTreatment
Panel III, American Heart Association/National
Heart, Lung and Blood Institute, and American
Diabetes Association) that emphasise targeting pri-
marily low density lipoprotein cholesterol in the
prevention of cardiovascular morbidity and
mortality.
85152Recent updates of the National Choles-
terol Education Program guidelines confirmed low
levelsofhighdensitylipoproteincholesterol(<40mg/
dl) as a major cardiovascular risk factor. Although the
guidelines recommend that clinicians should consider
combining a low density lipoprotein cholesterol low-
ering drug with a fibrate or niacin in patients with low
high density lipoprotein cholesterol, they refrained
from making recommendations about specific targets
for raising high density lipoprotein cholesterol
concentrations.
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